Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2017
<sup>18</sup>F-FDG PET/CT predicts survival after <sup>90</sup>Y transarterial radioembolization in unresectable hepatocellular carcinomaMario Jreige, Periklis Mitsakis, Axel Van Der Gucht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
Resin Versus Glass Microspheres for <sup>90</sup>Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model DosimetryAxel Van Der Gucht, Mario Jreige, Alban Denys, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 26, 2018
Guidelines on nuclear medicine imaging in neuroblastomaZvi Bar-Sever, Lorenzo Biassoni, Barry Shulkin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2013
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma studyAngela Di Giannatale, Nathalie Dias-Gastellier, Annick Devos, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2017
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1Gregory A Yanik, Marguerite T Parisi, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Rochelle Bagatell, Susan L Cohn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2017
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsRuth Ladenstein, Bieke Lambert, Ulrike Pötschger, et al.
Pageof 3